Drug-Induced Parkinsonism: Key Causes And Risk Factors

Clinical Presentation and Diagnosis in Drug-Induced Parkinsonism

The typical symptom profile in drug-induced Parkinsonism includes features such as bradykinesia (slowed movement), rigidity, and resting tremor. A distinctive aspect of this presentation is the frequent bilateral involvement, which contrasts with the more often unilateral onset of idiopathic Parkinson’s disease. Individuals may notice difficulty with fine motor tasks, changes in gait, or generalized slowness, with the timeline of onset often closely linked to the start or dose increase of a causative medication.

Diagnosis relies heavily on a detailed medical and medication history. Clinicians frequently perform a structured review of all recent and ongoing prescriptions, alongside a timeline correlating symptom emergence with medication changes. Physical examination findings, such as decreased arm swing or facial expression, may reinforce suspicions of drug-induced causes, particularly when classical features are present without other neurological findings.

Laboratory and imaging studies are typically used to rule out other conditions but may not demonstrate specific abnormalities in drug-induced Parkinsonism. Diagnostic confirmation often depends on improvement of symptoms following medication dose reduction or withdrawal, which may be guided by safety and psychiatric stability considerations. Persistence of symptoms even after cessation of the causative drug can occur in a subset of cases, often influenced by duration of exposure or preexisting vulnerabilities.

Distinguishing drug-induced from idiopathic forms supports more tailored care and medication management strategies. Recognizing the constellation of clinical features and maintaining awareness of drug-exposure history are key steps in the diagnostic process. The following page addresses risk factors and vulnerability within different population groups.